Protocol Number: CL0101-01. A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC).

October 21, 2015
Cancer - Lung
Principal Investigator: Benjamin Movsas, MD

The purpose of this research study is to test the safety of BIO 300, an experimental drug, at different dose levels and to study what effects (good and/or bad) BIO 300 has on your lung cancer. The study will help determine how BIO 300 interacts with chemotherapy and/or radiation and will help researchers decide the best dose of BIO 300.

Patients must have histologically or cytologically proven newly diagnosed Stage II, III or IV, primary non-small cell lung cancer (adenocarcinoma, large cell carcinoma, squamous or unspecified) with no more than 3 lung oligometastases.

Patients must have unresectable disease, inoperable or the patient has declined surgery. Alternatively, the subject is not a candidate for surgery based on concomitant medical conditions.

Patients with prior radiation to the chest region are not eligible unless the treating physician considers it unlikely to impact the clinical outcome of the patient.

Please call for further eligibility criteria.

Diane Snell
(313) 916-3124